Hepsor AS-i tütarett
Hepsor AS-i tütarettevõte rajab Tallinna kesklinna puidust kortermaja
02 sept. 2024 00h00 HE | HEPSOR AS
Hepsor AS-i tütarettevõte Hepsor V7 OÜ omandas kinnistu Tallinna südalinnas, aadressil Võistluse 7, kuhu on plaanis rajada unikaalne keskkonnasäästlik puidust kortermaja. Arendamisele tuleb...
Hepsor AS Subsidiary
Hepsor AS Subsidiary to Build a Wooden Apartment Building in Central Tallinn
02 sept. 2024 00h00 HE | HEPSOR AS
Hepsor V7 OÜ, a subsidiary of Hepsor AS, acquired a property in the heart of Tallinn, at Võistluse 7, where it is planned to build a unique environmentally friendly wooden apartment building. A...
arvinas_logoART_lg.jpg
Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update
30 juil. 2024 07h00 HE | Arvinas Inc.
– Completed enrollment in the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting; continued enrollment globally in multiple clinical trials of vepdegestrant in ER+/HER2-...
MRTX_Logo_PrimaryBlue_4CP.jpg
Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
09 mai 2024 07h00 HE | Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics today reported business highlights and financial results for the first quarter ending March 31, 2024.
arvinas_logoART_lg.jpg
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
07 mai 2024 07h00 HE | Arvinas Inc.
– Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study...
logo.png
ASSYSTEM: First-quarter 2024 consolidated revenue
25 avr. 2024 11h35 HE | ASSYSTEM
First-quarter 2024 consolidated revenue: €154.3m (up 7.2%) Organic growth: 5.5% vs Q1 20232023 dividend payment calendar Paris-La Défense, 25 April 2024, 5.35 p.m. (CEST) – Assystem S.A. (ISIN:...
arvinas_logoART_lg.jpg
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
11 avr. 2024 07h00 HE | Arvinas Inc.
– Arvinas to receive a $150 million upfront payment for the license of ARV-766 and the sale of Arvinas’ preclinical AR-V7 program, with the potential under the License Agreement for up to $1.01...
TellBio Logo.png
UPDATE – Tellbio’s Technology Demonstrates that Analysis of Circulating Tumor Cells Can Predict Survival Among Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Radium-223
27 mars 2024 08h34 HE | TellBio, Inc
-- AR-V7 expression in CTCs isolated with TellDx is an independent negative prognostic factor in patients receiving radium-223 -- -- Study shows promise of CTCs and AR-V7 as biomarkers for radium-223...
TellBio Logo.png
Tellbio’s Technology Demonstrates that Analysis of Circulating Tumor Cells Can Predict Survival Among Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Radium-2230
27 mars 2024 08h00 HE | TellBio, Inc
-- AR-V7 expression in CTCs isolated with TellDx is an independent negative prognostic factor in patients receiving radium-223 -- -- Study shows promise of CTCs and AR-V7 as biomarkers for...
NVIDIA Healthcare Microservices
NVIDIA Healthcare Launches Generative AI Microservices to Advance Drug Discovery, MedTech and Digital Health
18 mars 2024 17h16 HE | NVIDIA
SAN JOSE, Calif.—GTC, March 18, 2024 (GLOBE NEWSWIRE) -- NVIDIA today launched more than two dozen new microservices that allow healthcare enterprises worldwide to take advantage of the latest...